NCT02998567View on ClinicalTrials.gov

Combination Study of Guadecitabine/ASTX727 and Pembrolizumab

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 26, 2017

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Guadecitabine

In arm 1 (escalation) and 2 (expansion).

DRUG

Pembrolizumab

In arm 1 (escalation) and 2 (expansion).

DRUG

ASTX727

In arm B2 (lung expansion) replacing guadecitabine

Trial Locations (2)

SM2 5PT

RECRUITING

Royal Marsden Hospital, Sutton

W1T 7HA

RECRUITING

UCLH, London

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Institute of Cancer Research, United Kingdom

OTHER

lead

Royal Marsden NHS Foundation Trust

OTHER